Abstract: The present disclosure provides modified bacteria and modified peptidoglycan comprising modified D-amino acids; compositions comprising the modified bacteria or peptidoglycan; and methods of using the modified bacteria or peptidoglycan. The modified D-amino acids include a bioorthogonal functional group such as an azide, an alkyne or a norbornene group. Also provided are modified peptidoglycans conjugated to a molecule of interest via a linker.

Abstract: The present invention provides nanoparticles including a metallic core having a length along each axis of from 1 to 100 nanometers and a coating disposed on at least part of the surface of the metallic core, wherein the coating comprises polydopamine, along with methods for making and using such nanoparticles. The metallic core may be gold, silver or iron oxide and the polydopamine coating may have other substances bound to it, such as silver, targeting ligands or antibodies, or other therapeutic or imaging contrast agents. The disclosed nanoparticles can be targeted to cells for treating cancer or bacterial infections, and for use in diagnostic imaging.

Abstract: Compositions and methods for treating bacterial, fungal, and yeast infections in wounds are disclosed. The disclosed poloxamer-based pharmaceutical composition includes a micronized poloxamer composition base combined with one or more suitable active pharmaceutical ingredients (APIs), such as, antibacterial or antifungal, thereby resulting in a synergistic effect for the APIs. The micronized poloxamer composition within poloxamer-based pharmaceutical composition includes poloxamer 407 and poloxamer 188. Poloxamer-based pharmaceutical composition exhibits a particle size average of about 50 ?m, which enhance APIs solubility. Additionally, poloxamer-based pharmaceutical composition can be delivered in a plurality of dosage forms, such as, powders, sprays, ointments, pastes, creams, lotions, solutions, and patches, among others.

Abstract: Antimicrobial compositions, especially those useful when applied topically, particularly to mucosal tissues (i.e., mucous membranes), including a cationic antiseptic such as biguanides and bisbiguanides such as chlorhexidine and its various salts including but not limited to the digluconate, diacetate, dimethosulfate, and dilactate salts; polymeric quaternary ammonium compounds such as polyhexamethylenebiguanide; silver and various silver complexes; small molecule quaternary ammonium compounds such as benzalkoium chloride and alkyl substituted derivatives; di-long chain alkyl (C8-C18) quaternary ammonium compounds; cetylpyridinium halides and their derivatives; benzethonium chloride and its alkyl substituted derivatives; and octenidine. The compositions can also include an enhancer component, a surfactant, a hydrophobic component, and/or a hydrophilic component.

Abstract: An object of the present invention is to provide a patch preparation having an excellent skin permeability of medicament using an acid additional salt of basic medicament. Provided is a patch preparation comprising a support and an adhesive layer on one surface of the support, wherein the adhesive layer contains a basic medicament, a fatty acid-based ionic liquid, and potassium salts and/or potassium ions. Said potassium salts and/or potassium ions are generated as a result of reaction of an acid addition salt of the basic medicament with a compound capable of generating potassium ion in the adhesive layer.

Abstract: The present invention pertains to a composition containing an immunogenic cell preparation of killed Leptospira bacteria in an ethylenediaminetetraacetic acid solution. The invention also pertains to a vaccine to protect an animal against an infection with leptospira bacteria, wherein the vaccine comprises this composition. Also, the invention pertains to the use of ethylenediaminetetraacetic acid to stabilize an immunogenic preparation of killed Leptospira bacteria in a liquid carrier, by dissolving the ethylenediaminetetraacetic acid in the carrier.

Abstract: The invention provides a colon cleansing solution comprising: a) 300 to 800 mmol per liter ascorbate anion provided by a mixture of: (i) ascorbic acid and (ii) one or more salts of ascorbic acid the components (i) and (ii) being present in a molar ratio of from 1:4.5 to 1:7.0; and b) 10 to 200 g per liter polyethylene glycol. The invention also provides methods and kits associated with, or making use of the solutions, and compositions for the preparation of the solutions.

Abstract: The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described.

Abstract: Provided is a method for producing a hydrogel, which enables a hydrogel comprising polyethylene glycol to be produced under low peroxidase concentration conditions and physiological conditions. The method for producing a hydrogel involves crosslinking polyethylene glycol having two or more thiol groups using peroxidase in the presence of a phenol compound.

Abstract: The present invention relates to compositions and methods of inducing the self-renewal of stem/progenitor supporting cells, including inducing the stem/progenitor cells to proliferate while maintaining, in the daughter cells, the capacity to differentiate into hair cells.

Abstract: Provided are a composition for hot-melt extrusion which can be hot-melt extruded at a temperature lower than a conventional temperature and therefore free of heat-induced deactivation of a drug; and a method for producing a hot-melt extrusion product which is simpler than a spray-drying method. More specifically, provided is a composition for hot-melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more. Also provided is a method for producing a hot-melt extrusion product including a step of hot-melt extruding a composition for hot-melt extrusion including a drug and hypromellose acetate succinate having a hydroxypropoxy molar substitution of 0.40 or more at a hot-melt temperature of melting temperature of the hypromellose acetate succinate or higher, or at a hot-melt temperature equal to or higher than a temperature at which both the hypromellose acetate succinate and the drug become melted.

Abstract: Nutritional supplement compositions that may provide sub-cellular phytonutrient delivery include a carrier oil base containing at least one triglyceride and also contain at least one biologically active complex in the carrier oil base. The biologically active complex may include a non-covalent complex of a carbon-60 fullerene, phytonutrient compound, and a triglyceride from the carrier oil base. The phytonutrient compound may be chosen from compounds having the ability to form non-covalent complexes with six-membered aromatic rings of carbon-60 fullerene. Examples of such phytonutrient compound include, for example, phenolic compounds, polyphenolic compounds, phenolic acids, flavonoids, terpenoids, tannins, stilbenes, curcuminoids, coumarins, lignans, quinones, phenylethanoids, carotenoids, astaxanthin, zeaxanthin, or coenzyme Q10. The nutritional supplement compositions may include multiple biologically active complexes in which the phytonutrient compounds are derived from olives, algae, or both.

Abstract: The present invention relates to an immunogenic composition comprising a continuous aqueous phase and a dispersed phase as droplets and comprising: an amphiphilic lipid, a solubilizing lipid comprising at least one fatty acid glyceride, a co-surfactant comprising at least one chain consisting of alkylene oxide units, a surfactant bearing an antigen of the following formula (I): (L1-X1—H1—Y1)v-G-Z1—Ag??(I), to its preparation method and its uses, notably for producing antibodies, as a drug or in an immunization method.

Abstract: A binding moiety (B) for Carbonic Anhydrase IX (CAIX), the binding moiety comprising: The binding moiety is univalent, bivalent, or multivalent. A targeted therapeutic agent may comprise the binding moiety. The invention also includes a method for treating a disease expressing elevated levels of CAIX by administering the targeted therapeutic agent.

Abstract: There is described inter alia a medical device having a surface which comprises a coating layer, said coating layer being a biocompatible composition comprising an anti-coagulant entity capable of interacting with mammalian blood to prevent coagulation or thrombus formation, which anti-coagulant entity is covalently attached to said surface through a linker comprising a thioether.

Abstract: The invention encompasses therapeutic formulations comprising a protein active ingredient and a stabilizing excipient, methods of improving stability in a therapeutic formulation comprising a protein active ingredient by adding a stability-improving amount of a stabilizing excipient to the therapeutic formulation, and methods of reducing adverse infusion-related effects in a patient, comprising administering to a patient in need thereof a therapeutic formulation comprising a protein active ingredient and a stabilizing excipient.

Abstract: Embodiments herein include polynucleotides, vectors and methods for the insertion and expression of transgenes. In an embodiment, a polynucleotide is included. The polynucleotide can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. In an embodiment, a recombinant vector is included. The recombinant vector can include a JeT promoter or variant thereof, an intron sequence less than 400 bases in length, and a polynucleotide sequence encoding a polypeptide or protein operatively linked to the promoter. Other embodiments are also included herein.

Abstract: The present invention relates to dual activation of Akt/NF?B pathway by DMA (5-(4-methylpiperazin-1-yl)-2-[2?-(3,4-dimethoxyphenyl)-5?-benzimidazolyl]benzimidazole) to render radioprotection both in mammalian cells and in Balb/c mice. Further it selectively protects normal cells overs tumor tissues against lethal total body irradiation (TBI) and there was no activation of Akt/NF?B pathway by DMA in response to radiation in tumor tissues. A single dose of DMA before TBI protect mice from GI and HP acute radiation syndrome (ARS) and offered radioprotection through oral, i.v., i.p., and s.c route of administration. The half life of DMA in plasma is 3.5 h at oral dose and 90% clearance was observed in 16 h. DMA accumulates in high concentration in intestine, liver, kidney and spleen tissues, justifying the observed radioprotection to normal tissue even at single dose.

Abstract: The present invention relates to nanoparticle compositions and treatment of cardiovascular disease using nanoparticles to target Class A and B scavenger receptors. This invention further relates to methods of detecting cells that express scavenger receptors, detecting atherosclerotic lesions, and targeting bioactive amphiphilic macromolecules to cells that express scavenger receptors.

Abstract: An imaging agent comprising a conjugate of an oligosaccharide moiety with an imaging moiety. The oligosaccharide is Lewis A or Lewis B or a mimetic thereof, or a pharmaceutically acceptable salt or PEGylated form of Lewis A or Lewis B or its mimetics. Lewis A and Lewis B and its mimetics are also provided for use in the therapeutic treatment of inflammatory diseases, autoimmune diseases and cancer.

Abstract: The present invention generally relates to the field of radiopharmaceuticals and their use in nuclear medicine as tracers, imaging agents and for the treatment of various disease states of prostate cancer.

Abstract: A compound represented by formula (I) is provided, wherein in formula (I), R1 and R2 each independently represents hydrogen, O—R3 or S—R4, at least one of R1 and R2 is O—R3 or S—R4, and R3 and R4 are independently a C1 to C10 alkyl group, such that the C1 to C10 alkyl group is non-substituted or substituted with at least one selected from the group consisting of —OH, —NH2, halogen, ester, ether, and carboxylic acid, and M being a metal or a metal-containing compound. The compound represented by formula (I) is shown to have higher specificity to tumor cells, and is therefore suitable for carrying anti-cancer drugs and/or nuclear imaging agents.

Abstract: The disclosure is related to a chemical structure, a preparation and an imaging method of a tumor imaging tracer, especially to a SPECT radionuclide-labeled trimeric cyclic RGD peptide: 99mTc-4P-RGD3which functions as a ligand to be combined with integrin ?v?3 receptor in tumor for tumor imaging. The preparation includes linking HYNIC-OSu with 4P-RGD3 to form HYNIC-4P-RGD3 and then chelating HYNIC with 99mTc to create 99mTc-4P-RGD3Animal biodistribution and imaging experiments reveal higher uptake in tumor and lower uptake in normal organs, therefore the disclosure can improve image quality, Through animal metabolic experiments, the original form of 99mTc-4P-RGD3 can be still excreted without the evidence of further metabolites in urine and feces. According to the disclosure, the tumor imaging tracer 99mTc-4P-RGD; combined with the integrin ?v?3 solves the issue of high background uptake in normal organs, such that radio-labeled SPECT imaging tracers are more suitable for animal whole-body tumor evaluation.

Abstract: A vaginal preparation for the diagnosis of human female uterotubal patency and function, comprising particles having a nucleus absorbable by the tissues of the human body, and a coating for the nucleus which is dissolvable and non-absorbable by the tissues of the human body, inert and innocuous, the nucleus comprising at least one marker that can be released by the human body through an organic fluid, the coating being dissolvable and sensitive, for the purpose of the dissolution thereof, to time and/or changes in pH and/or temperature and/or another chemical/physical parameter along the route from the vaginal area to the tubal and pelvic area, the particles having a size, weight and ovoid shape corresponding approximately to those of spermatozoa.

Abstract: The device for diffusing volatile substances comprises means for generating an air stream, and is characterized in that said means for generating an air stream comprise a flexible sheet (1) and at least one piezoelectric element (2), such that said piezoelectric element (2) causes said flexible sheet (1) to expand and shrink to generate the air stream. It allows generating an air flow that is adapted to the geometry of the evaporation surface.

Abstract: The invention provides a solution to the drawbacks associated with conventional alginate dressings. This invention features improved alginate dressings or bandages as well as a fabrication process that results in an alginate sheet that is preloaded with drug, can be stored in a freeze-dried state, and is compliant and ready to use at the time of administration.

Abstract: Compositions having antimicrobial activity contain surface functionalized particles comprising an inorganic copper salt which has low water solubility. These types of inorganic salts may also be introduced in porous particles to yield antimicrobial compositions. The compositions may optionally comprise additional antimicrobial agents, salts with high water solubility, organic acids, salts of organic acids and their esters. The above compositions can be incorporated in a variety of wound care products to provide antimicrobial properties.

Abstract: The present invention relates to a paste-powder binary bone cement used in arthroplasty or vertebroplasty, and, more particularly, to a paste-powder binary bone cement which can be directly used at a site to be treated without additionally waiting it to the site by dissolving predetermined chemically-unreactive powdered compositions in a liquid monomer to form paste having high viscosity and then mixing other powdered components with the paste in a minimum amount of air, and to an apparatus for injecting the same.

Abstract: In one embodiment, the present invention includes a method for repairing a cartilage defect including: preparing a cartilage defect by removing unwanted or damaged tissue; creating at least one perforation into or through subchondral bone, below and/or adjacent to the cartilage defect to induce the flow of bone fluid; allowing the bone fluid to bleed through the at least one perforation up into the cartilage defect to fill at least a portion of the cartilage defect; and applying a biomaterial into the defect to produce a clot for cartilage regeneration.

Abstract: Products, processes, compositions, kits, and methods are provided for cartilage-derived implants. The implants can exhibit resistance to enzyme (e.g., collagenase, protease, etc.) digestion compared to the source tissue from which they were derived while still having one or more mechanical properties comparable to the source tissue from which they were derived. The implants can also have a plurality of molecular bridges between molecules of the cartilaginous material. The molecular bridges can connect one or more collagen fibrils and/or/with one or more glycosaminoglycans. The implants can also be treated with cationic detergent, packaged and sterilized with or without additional components, and surgically implanted into subjects.

Abstract: Biomaterials, implants made therefrom, methods of making the biomaterial and implants, methods of promoting bone or wound healing in a mammal by administering the biomaterial or implant to the mammal, and kits that include such biomaterials, implants, or components thereof. The biomaterials may be designed to exhibit osteogenic, osteoinductive, osteoconductive, and/or osteostimulative properties.

Abstract: A vascular implant made in total or in parts of a biodegradable magnesium alloy consisting of Y: 2.0-6.0% by weight, Nd: 1.5-4.5% by weight, Gd: 0-4.0% by weight, Dy: 0-4.0% by weight, Er: 0-4.0% by weight, Zr: 0.1-1.0% by weight, Li: 0-0.2% by weight, Al: 0-0.3% by weight, under the condition that a) a total content of Er, Gd and Dy is in the range of 0.82-4.0% by weight and b) a total content of Nd, Er, Gd and Dy is in the range of 2.98-8.5% by weight, the balance being magnesium and incidental impurities up to a total of 0.3% by weight.

Abstract: A method for making a graft layer is provided. The graft layer has at least two layers with different porosities. The two layers are applied by electrospinning. The parameters of the electrospinning may be varied when applying the first and second layers in order to achieve different porosities of the first and second layers.

Abstract: The present invention generally relates to articles of manufacture, such as medical devices, having a non-fouling surface comprising a grafted polymer material. The surface resists the adhesion of biological material.

Abstract: Coatings, devices and methods are provided, wherein the contacting surface of a medical device with at least one contacting surface for contacting a bodily fluid or tissue, wherein long-lasting and durable bioactive agents or functional groups are deposited on the contacting surface through a unique two-step plasma coating process with deposition of a thin layer of plasma coating using a silicon-containing monomer in the first step and plasma surface modification using a mixture of nitrogen-containing molecules and oxygen-containing molecules in the second step. The two-step plasma coating process enables the implantable medical device to prevent both restenosis and thrombosis under clinical conditions. The invention also relates to surface treatment of metallic and polymeric biomaterials used for making of medical devices with significantly improved clinical performance and durability.

Abstract: The present invention relates to protein biocoacervates and biomaterials vessel graft systems used in cardiovascular applications and other medical applications, the components utilized in the vessel graft systems and the methods of making and using such systems. More specifically the present invention relates to protein biocoacervates and biomaterials vessel graft systems used in various medical applications and/or the devices used in such vessel graft systems including, but not limited to, vessel grafts as drug delivery devices for the controlled release of pharmacologically active agents, tubular grafts, vascular grafts, protein biomaterial sutures and biomeshes, protein biomaterial adhesives and glues, and other biocompatible biocoacervate or biomaterial devices used in the vessel graft systems of the present invention.

Abstract: The present disclosure provides medical devices possessing reactants thereon, which further promote adherence of the device to tissue in vivo and/or release of bioactive agents from the device.

Abstract: Various aspects of the present invention provide compositions and implantable devices including a water-insoluble therapeutic agent solubilized in a matrix of a gallate-containing compound. Other aspects provide methods of manufacturing and using such compositions and devices.

Abstract: Compositions containing chlorhexidine gluconate solubilized in hydrophobic vehicles are described. Resin systems containing such chlorhexidine gluconate compositions, including adhesives and articles incorporating such resin systems, including medical articles such as drapes are also described.

Abstract: The illustrative embodiments described herein are directed to an apparatus and method for managing reduced pressure at a tissue site. The apparatus includes a reduced pressure source that generates reduced pressure. The reduced pressure is delivered to the tissue site via a delivery tube. The apparatus includes a single pressure sensor. The single pressure sensor detects an actual reduced pressure at the tissue site. The apparatus also includes a controller. The controller determines a responsiveness of the actual reduced pressure measured by the single pressure sensor to an increase in reduced pressure generated by the reduced pressure source. The apparatus includes an indicator. The indicator emits a signal when the controller determines that the actual reduced pressure measured by the single pressure sensor is nonresponsive to the increase in reduced pressure generated by the reduced pressure source.

Abstract: A manually-actuated pump for applying reduced-pressure therapy includes a charging chamber and a regulated chamber. The charging chamber has a closed end. A regulator passage extends between the charging chamber and the regulated chamber, and a valve body is adapted to control fluid communication through the regulator passage. A regulator spring is engaged with the valve body to bias the valve body against a differential between a pressure in the regulated chamber and an ambient pressure. The manually-actuated pump also includes an outlet port coupled to the regulated chamber; and a valve assembly coupled to the charging chamber to permit fluid flow through the closed end of the charging chamber.

Abstract: A fluid flow controller includes a first body portion defining a receiving surface, a second body portion, and a fluid transfer device. The second body portion includes a controller engagement member, and is configured to couple to the first body portion such that the controller engagement member faces and is spaced from an engagement point of the receiving surface. The controller engagement member is configured to be adjusted from a first distance to a second distance closer to the engagement point than the first distance based on a force applied by a foot pedal apparatus. The fluid transfer device defines a flow channel configured to be adjusted from defining a first cross sectional area to a second, lesser cross sectional area while the controller engagement member is in contact with the first fluid transfer device and adjusted towards the second distance in response to the applied force.

Abstract: Wound treatment systems and methods (e.g., having hydrophilic wound inserts), such as for negative-pressure and/or fluid-installation wound therapies. Some embodiments include a check-valve assembly between a wound dressing and a vacuum source.

Abstract: A wound fluid collection system includes a canister with a chamber fluidly connected to a wound dressing in a tissue site through an inlet and also fluidly connected to a reduced pressure source through an outlet. At least a portion of the canister is collapsible and yet can be maintained in an extended state when exposed to subatmospheric pressure. The canister is releasably attachable to a supporting member.

Abstract: Systems, methods, and apparatuses for providing feedback for reduced-pressure therapy are described. A regulator can include a supply chamber fluidly coupled to a dressing, a control chamber fluidly coupled to the dressing, a charging chamber fluidly coupled to the supply chamber through a port, and a regulator valve operable to control fluid communication through the port based on a pressure differential between the control chamber and a target pressure. The feedback system can include a printed circuit board, a pressure sensor and a signal interface communicatively coupled to the printed circuit board. The pressure sensor can be fluidly coupled to the control chamber to determine the pressure in the control chamber. The signal interface can indicate a state of the reduced-pressure therapy. A potential source can be communicatively coupled to the printed circuit board, the pressure sensor, and the indicator.

Abstract: A dressing for treating a tissue site may include a base layer, a sealing member, a first and a second wicking layer, and an absorbent layer. The base layer may have a periphery surrounding a central portion and a plurality of apertures disposed through the periphery and the central portion. The apertures in the periphery may be larger than the apertures in the central portion. The sealing member and the base layer may define an enclosure. The first and the second wicking layer may each be disposed in the enclosure with the absorbent layer positioned between the first and the second wicking layer. Other dressings, systems, and methods are disclosed.

Abstract: A composite wound dressing and delivery apparatus includes a substantially transparent dressing layer having a lower surface that is coated with a pressure sensitive for applying the dressing layer over a wound to define a reservoir in which a negative pressure may be maintained. A substantially transparent backing layer adhered to the lower surface of the dressing layer in a releasable manner, and a vacuum port is centrally located on the dressing layer. The vacuum port is adapted to provide fluid communication between a vacuum source and the reservoir through the dressing layer. A targeting grid associated with either the dressing layer or the backing layer includes regularly spaced reference marks along at least two axes extending from the vacuum port.

Abstract: The present invention relates to a suction device. The suction device comprises an attachment portion adapted to be attached to a wound cover member. The suction device comprises a fluid inlet which is at least partially circumscribed by the attachment portion. The suction device also comprises a fluid outlet. The suction device further comprising a connection portion adapted to, at least during one operation condition of the suction device, provide a fluid communication between the fluid inlet and the fluid outlet. The connection portion comprises an inspection portion that is transparent to thereby facilitate the positioning of the suction device relative to the wound cover member.

Abstract: A breast pump system includes a duckbill-style check valve that intermittently releases breast milk from a charging chamber to a storage chamber. Various examples of rotational interlocks ensure that the valve is properly installed to avoid interference between the valve's discharge end and the inner surface of an outer shell that contains the valve. In some examples, the outer shell includes a concavity or other feature configured to accommodate multiple rotational positions of the valve.

Abstract: A pump apparatus and method for extracting breast milk is disclosed. The pump includes a first interface component to stimulate a Milk Ejection Reflex (MER) and a second interface component to extract breast milk. Milk is extracted through an improved method that more closely replicates the suckling of an infant.